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sequence of reactive T cells. Hence, the complex and diverse 
clinical manifestations of delayed-type hypersensitivity are 
caused by the functional heterogeneity of T cells. In the aba-
cavir model of p-i HLA, the drug binding to HLA may result 
in alteration of the presenting peptides. More importantly, 
the drug binding to HLA generates a drug-modified HLA, 
which stimulates T cells directly, like an allo-HLA. In the sul-
famethoxazole model of p-i TCR, responsive T cells likely re-
quire costimulation for full T cell activation. These findings 
may explain the similarity of delayed-type hypersensitivity 
reactions to graft-versus-host disease, and how systemic vi-
ral infections increase the risk of delayed-type hypersensitiv-
ity reactions.  © 2015 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Drug hypersensitivity reactions (DHR) are the result 
of immune interactions with small molecular compounds 
or proteins used as drugs  [1] . Immune reactions to pro-
teins, which represent complete antigens per se, are not 
discussed here  [2] . Reactions to small molecules include 
allergic, pharmacological  (p-i) and nonallergic (‘pseudo-
allergic’) hypersensitivity reactions.
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 Abstract 
 Small chemicals like drugs tend to bind to proteins via non-
covalent bonds, e.g. hydrogen bonds, salt bridges or electro-
static interactions. Some chemicals interact with other mol-
ecules than the actual target ligand, representing so-called 
‘off-target’ activities of drugs. Such interactions are a main 
cause of adverse side effects to drugs and are normally clas-
sified as predictable type A reactions. Detailed analysis of 
drug-induced immune reactions revealed that off-target ac-
tivities also affect immune receptors, such as highly poly-
morphic human leukocyte antigens (HLA) or T cell receptors 
(TCR). Such drug interactions with immune receptors may 
lead to T cell stimulation, resulting in clinical symptoms of 
delayed-type hypersensitivity. They are assigned the ‘phar-
macological interaction with immune receptors’ (p-i) con-
cept. Analysis of p-i has revealed that drugs bind preferen-
tially or exclusively to distinct HLA molecules (p-i HLA) or to 
distinct TCR (p-i TCR). P-i reactions differ from ‘conventional’ 
off-target drug reactions as the outcome is not due to the 
effect on the drug-modified cells themselves, but is the con-
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 Allergic, immune-mediated reactions are based on the 
covalent binding of small chemicals to protein or peptide 
molecules, which generates new antigenic determinants 
consisting of either hapten-protein or hapten-peptide 
complexes  [3, 4] . These complexes have an immunostim-
ulatory potential since they provide antigenic epitopes to 
B cells and immunoglobulins. Processing of these com-
plexes may furthermore generate antigenic hapten-pep-
tides which have the ability to stimulate T cells in a human 
leukocyte antigen (HLA)-dependent manner. Impor-
tantly, haptens can also stimulate innate immunity and 
activate dendritic cells, meeting an important require-
ment for the induction of a novel immune response  [5–7] . 
 Pharmacological hypersensitivity reactions according 
to the p-i (pharmacological interaction with immune re-
ceptor) concept are based on the noncovalent binding of 
drugs or metabolites to immune receptor proteins them-
selves (HLA or T cell receptors, TCR)  [8–11] . The bind-
ing of a drug to an immune receptor follows the same 
rules as a drug binding to a nonimmunological receptor. 
Typically, drug binding to a receptor is rapid, based on 
noncovalent interactions and is reversible  [10] . Drug hy-
persensitivity reactions (DHR) according to the p-i con-
cept do not require the processing of a new antigenic 
complex and neither metabolism of the drug nor subse-
quent processing steps are required ( table 1 ). In pharma-
cological hypersensitivity, complex immune responses 
encompassing dendritic cell activation and subsequent 
stimulation of B and T cells do not occur. Rather, a typical 
feature of p-i stimulation is its restriction to T cells alone 
as the drugs bind to immune receptors involved in T cell 
activation  [12] . The final result of p-i stimulation is simi-
lar to  allergic immune-mediated T cell reactions and can 
lead to a quite heterogeneous clinical picture  [12] .
 Pseudo-allergic  or  nonallergic hypersensitivity reac-
tions are characterized by direct drug interactions with 
inflammatory effector cells, in particular mast cells, baso-
phils and eosinophils, and probably also neutrophils. In 
response to a drug, inflammatory cells degranulate or 
produce and release a large amount of inflammatory me-
diators, such as leukotrienes. In contrast to allergic and 
pharmacological stimulations, there is no evidence that 
the adaptive immune system is involved. Clinically, the 
most frequent form of pseudoallergic reactions are due to 
NSAIDs where rapid onset of either cutaneous manifes-
tations (e.g. urticaria or angioedema) or respiratory man-
ifestations (e.g. rhinosinusitis or bronchospasm) occur 
 [13] . In NSAID-triggered reactions a shift to enhanced 
leukotriene production has been described, but for most 
pseudoallergic reactions the underlying mechanisms are 
unknown and probably differ between different drugs 
and drug classes. In some pseudoallergic or nonallergic 
 Table 1.  Immune/allergic and pharmacological hypersensitivity reactions
Hapten concept (immune/allergic stimulation) p-i concept (pharmacological stimulation)
Generation of a complex immune response with 
activation of the innate immune system, T and B 
cell reactions
Direct and exclusive T cell stimulation by 
‘pharmacological’ drug-receptor interaction; innate 
immune system not involved
Chemical (covalent) stable binding of drug/drug 
metabolite to proteins or peptides, which act as 
antigens for B and T cells
Structural binding of drug/drug metabolite to certain 
HLA or TCR proteins; mostly quite labile interactions
Can be dependent on the metabolism of the drug 
to reactive compound and needs processing of 
proteins to immunogenic peptides
Metabolism of drugs or processing of proteins are not 
required to elicit reactivity
Time for drug metabolism and protein processing 
within APC is needed (>~4 h)
Mostly immediate (<~10 min) reactivity of T cells1
B and T cells react via specific immune receptors 
to drug-modified proteins or drug-modified 
peptides
T cells react via TCR directly to the drug-modified 
HLA/peptide complex, or the drug has an allogeneic 
effect on TCR which then reacts to the HLA peptide
 1 Abacavir reactivity may need more time if loading onto HLA-B*57:01 occurs inside the endoplasmic reticu-
lum (see text).
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hypersensitivity reactions, the drug is cationic and can 
interact with a human G-protein-coupled receptor, 
MRGPRX2, on mast cells and lead to IgE-independent 
mast cell degranulation  [14] . 
 This review focuses on p-i-driven T cell stimulations 
which can be differentiated into ‘p-i HLA’ (drug binding 
to HLA) and ‘p-i TCR’ (drug binding to TCR)  [15] . The 
drug binding to immune receptors per se can result in par-
tial T cell activation where costimulation is required or 
can result in complete T cell activation. The later includes 
the abacavir model of p-i HLA where drug binding to the 
peptide-HLA complex (peptHLA) mimics an allo-allele. 
 p-i HLA and p-i TCR  
 Over the last few years, the interaction of small mole-
cules with immune receptors and its functional conse-
quences have become a fascinating new research topic. 
Studies of T cells from patients revealed that DHR can be 
due to direct stimulation of T cells according to the p-i 
concept  [8–11] . The partners involved in the p-i concept 
are the drug, TCR on T cells, and peptHLA on the target 
cell, which can be antigen-presenting cells (APC) or any 
tissue cell expressing HLA ( fig. 1 ). Only the presence of 
 these three components leads to effector functions of
T cells such as proliferation, cytokine secretion and cyto-
toxicity, and these can result in highly variable clinical 
pictures  [12] . Depending on the preferential binding to 
either HLA or TCR, two types of p-i mechanisms can be 
discriminated: p-i HLA and p-i TCR  [15] . All data regard-
ing p-i HLA and p-i TCR involve αβ-TCR and the subse-
quent T cell stimulations. Stimulations of B cells or NK 
cells by noncovalent drug binding to their immune recep-
tors have so far not been demonstrated.
 p-i HLA 
 A decisive step forward in understanding severe,
T cell-mediated DHR was the discovery of HLA allele as-
sociations with severe DHR  [16–20] . These associations 
have been described for a growing number of drugs [re-
viewed in  21 ]. Some of these have almost exclusive asso-
ciations with certain HLA alleles, providing negative pre-
dictive values approximating 100%, while the positive 
predictive values tend to be low (<3%). A notable excep-
tion is abacavir hypersensitivity syndrome where about 
55% of HLA-B * 57: 01 + carriers developed a hypersensitiv-
ity reaction upon drug exposure  [22] . 
 The relative risk of developing HLA-associated DHR 
depends on the frequency of the involved allele in a given 
population. Carbamazepine-induced Stevens-Johnson 
syndrome/toxic epidermal necrolysis (SJS/TEN) in Han 
a b c d
 Fig. 1. Drug hypersensitivity: from clinic to molecular models.  a A 
patient with a maculopapular drug eruption.  b Histology of T cell 
infiltration into the dermis and epidermis, and killing of keratino-
cytes by cytotoxic T cells (red = granzyme B staining of infiltrating 
T cells).  c Scheme of the interaction of T cell/TCR with the {drug-
peptHLA} complex on the APC/target cell.  d Crystallographic 
structure of TCR (red), HLA class I molecule (green) and embed-
ded peptide (yellow); stars indicate possible binding sites of a drug 
to the immune receptor protein itself (TCR or HLA, according to 
the p-i concept). 
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Chinese were strongly linked to HLA-B * 15: 02  [17] , but 
this association could not be confirmed in Europeans, 
where HLA-B * 15: 02 is rare  [23] . In Europeans, carba-
mazepine-induced hypersensitivity was linked to HLA-
A * 31: 01, and mainly manifested as a drug rash with eo-
sinophilia and systemic symptoms (DRESS), and less as 
SJS/TEN  [23, 24] . In general, the majority of high-risk 
alleles for DHR were HLA class I, but some less stringent 
associations were also found for HLA class II alleles  [25, 
26] , mostly resulting in less severe DHR. 
 In vitro studies revealed that DHR with strong HLA as-
sociations were not due to the modification of a peptide by 
a covalently bound drug or drug metabolite. Neither car-
bamazepine nor abacavir hypersensitivity peptides eluted 
from purified HLA molecules of drug-pulsed APC carried 
a covalently bound drug  [27–30] . Indeed, a highly selective 
HLA allele association argues against the involvement of a 
hapten-driven T cell stimulation. Haptens bind to multiple 
binding sites in a protein which, after processing to hapten 
peptides, would be loaded on different rather than only 
one HLA molecule  [31] . Thus, if a DHR against a distinct 
molecule is exclusively restricted to a unique HLA allele, it 
may be argued that the small drug molecule itself rather 
than a specific peptide is involved.
 The Altered Peptide Model of p-i HLA  
 A breakthrough in understanding the link between 
DHR and HLA association was the crystallographic struc-
ture of the HLA-B * 57: 01 molecule with bound abacavir 
 [29, 30] . It showed that the drug binds below  the peptide 
presented by the HLA-B * 57: 01 molecule, away from the 
site of peptide-TCR interaction  [28, 29] . Analysis of pep-
 Fig. 2. p-i HLA: modification of HLA-B * 57: 01 molecules by aba-
cavir occurs via extracellular and intracellular pathways. Via the 
extracellular pathway, abacavir molecules may directly bind to the 
F9-pocket of peptHLA-B * 57: 01 complexes presented on the cell 
surface. Given the fact that HLA-embedded peptides exhibit a cer-
tain degree of flexibility, abacavir could get temporary access to the 
peptide-binding groove of peptHLA molecules. In order to gener-
ate a sufficient number of {abacavir-peptHLA-B * 57: 01} complex-
es, a relatively high abacavir concentration is required (10 μg/ml) 
 [35, 36] . Via the intracellular pathway, drug (abacavir) molecules 
are transported into cells and enter the endoplasmic reticulum, 
where peptide loading onto the available HLA class I molecules 
takes place. In the case of abacavir, the drug competes with pep-
tides for the binding to the still empty F9 pocket of HLA-B * 57: 01. 
As abacavir seems to have a rather high affinity for the F-pocket, 
quite low abacavir concentrations (0.01 μg/ml) are sufficient to 
bind to and thus modify a substantial amount of HLA-B * 57: 01. 
This has two consequences: (i) the abacavir binding alters the pep-
tide-binding capacity of HLA-B * 57: 01. In addition and/or instead 
of usual peptides, altered peptides are selected for binding to {ab-
acavir-HLA-B * 57: 01}  [28–30] ; (ii) moreover, the abacavir binding 
makes the {abacavir-HLA-B * 57: 01} complex look like a foreign 
(allo) HLA-protein. The {abacavir-peptHLA} complex is trans-
ported to the cell surface, where it elicits an auto- and predomi-
nantly an allo-like immune reaction  [40] . The stimulation by an 
abacavir-induced TCC occurs independently of extracellular or 
intracellular abacavir loading on HLA-B * 57: 01. This argues for
a poly-specificity of the reactive T cells  [35] – not so much the
particular peptide but the whole configuration of the {abacavir-
peptHLA} complex seems to elicit T cell reactivity  [35, 40] .  
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tides eluted from abacavir-treated HLA-B * 57: 01 + APC 
revealed that approximately 20% of the eluted peptides 
were absent in the pool of peptides eluted from abacavir-
untreated HLA-B * 57: 01 molecules  [28–30] . The data 
suggest that when abacavir is incubated with APC, it is 
taken up, enters the endoplasmic reticulum, and binds 
the still empty F-pocket of HLA-B * 57: 01 via noncova-
lent bonds ( fig. 2 ,  3 ). This changes the peptide-binding 
ability of HLA-B * 57: 01; instead of binding normal HLA-
B * 57: 01-anchored peptides with tryptophan at the anchor 
residue, peptides with a small aliphatic amino acid (valine, 
isoleucine and leucine) at this position are favored. As 
such, peptides are novel and are not presented in the ab-
sence of abacavir, and they may induce an autoimmune 
reaction. Therefore, in this ‘altered peptide repertoire 
model’ DHR is a kind of autoimmune reaction  [32] . 
 The Allo-Immune Model of p-i HLA  
 Data for the altered peptide model for DHR rely exclu-
sively on the analysis of abacavir-exposed APC, as altered 
peptides were not convincingly described in other HLA-
associated DHR. The data on carbamazepine are some-
what controversial (see below)  [28, 33, 34] . Moreover, the 
analysis of drug-reactive T cells induced to abacavir, al-
lopurinol, oxypurinol and flucloxacillin suggest another 
possibility ( fig. 2 ): drug binding can immediately  alter the 
whole configuration of the peptHLA complex without 
peptide exchange. All allopurinol/oxypurinol-reacting
T cell clones (TCC), most flucloxacillin-reacting TCC 
and approximately 40% of abacavir-reacting TCC reacted 
immediately (<5 min) to the respective drugs in the pres-
ence of APC as shown by Ca ++ -influx assays. The speed 
of this reaction in the reactive T cells rules out the possi-
bility of internal loading and peptide exchange in the 
APC  [35–37] . How does a drug molecule access its bind-
ing site when it is hidden beneath the anchored peptide? 
The answer may lie in the flexibility of peptHLA com-
plexes. Studies on HLA-B * 27: 05- and HLA-B * 27: 09-bind-
ing peptides showed that HLA-bound peptides are not 
always fixed within the binding groove and that some 
movements out of the groove are possible  [38] . Yun et al. 
 [36] proposed that the flexibility of HLA-binding pep-
tides may allow drug binding to the HLA pockets despite 
the presence of a peptide. Peptide flexibility would lead to 
partial detachment of the peptide, thereby exposing the 
drug-binding site. This would allow the drug molecule to 
bind to the relevant site, e.g. the F-pocket in the peptide-
binding groove. This rapidly formed peptide-drug-HLA 
complex would be immunogenic in a way that is similar 
to an allo-HLA causing direct allo-recognition by T cells 
a
b
c
 Fig. 3. p-i HLA: abacavir binding to HLA B * 57: 01 and its imitation 
of B * 58: 01: direct allo-stimulation as an explanation for drug hy-
persensitivity. A model of the peptide-binding groove (F pocket) 
of HLA-B * 57: 01 with abacavir docked ( a ), or HLA-B * 58: 01 with-
out abacavir ( b ). The peptide IALYLQQNV was chosen as it is
able to bind to both B * 57: 01 (with or without abacavir) as well as 
B * 58: 01  [40] . Note that the abacavir in B * 57: 01 provides a bulging 
of the peptide similar to the arginine of position 96 (shown as a 
stick model) in B * 58: 01. The model explains the cross-reactivity of 
some abacavir/pept/HLA-B * 57: 01-induced TCC with B * 58: 01 
 [40] .  c Overlay of energy-minimized peptides from HLA B * 57: 01 
plus abacavir (blue) and B * 58: 01 (orange). Minor differences also 
occur in the α2 helix (lower helix) [for details of binding in the F9-
pocket, see ref.  28,  29 ; see ref.  40 for cross-reactivity with HLA-
B * 58: 01]. 
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 [39] . The direct pathway of allo-stimulation results from 
the recognition of intact, foreign peptide-MHC complex-
es on the surface of donor cells. Of note, about 5–20% of 
circulating T cells are directly stimulated by an allo-pro-
tein and this forms the basis for rapid transplant rejection 
and acute graft-versus-host disease (GVHD). 
 This allo-immune concept for DHR was based on a 
detailed analysis of abacavir-induced TCC  [40] , which re-
vealed some features similar to direct allo-recognition, 
where a direct interaction of the TCR with allo-peptHLA 
results in an immediate T cell activation  [39] ( table 2 ). 
Adam et al.  [40] found that abacavir-stimulated T cells 
can be induced in the absence of dendritic cells and that 
they stemmed from both the naïve and memory T cell 
pool. The stimulation of naïve T cells by abacavir was re-
cently confirmed by Lucas et al.  [43] . Both features are 
unusual for ‘normal’ peptide reactivity, but well docu-
mented for direct allo-stimulation  [39, 41, 42, 44] . More-
over, when 136 abacavir-reacting TCC from 3 HLA B * 57: 
 01 + donors were analyzed, in each of the donors 5% of the 
abacavir-reacting TCC also reacted to HLA-B * 58: 01-pep-
tide complexes (in the absence of abacavir)  [40] . Docking 
and modeling studies suggested that this allo-reactivity
of abacavir reacting TCC was due to the similarity of
{abacavir-pept-B * 5 7 :01} complexes to {pept-B * 5 8 :01} 
complexes, leading to the assumption that noncovalent 
drug binding to a self HLA protein (HLA-B * 57: 01) can 
transform it to look like an allogeneic HLA protein 
(namely like HLA-B * 58: 01;  fig. 3 ).  Table 2 summarizes 
the similarities of allo- and drug stimulations.
 An interesting but not yet well documented aspect of 
abacavir-induced T cell responses is the polyspecificity of 
the reactive T cells. Polyspecificity refers to the ability of 
T cells to react with more than one peptide. It is assumed 
to be frequent in allo-reactions  [44, 45] where the pep-
tides are presented by an allo-allele. It might explain the 
strength of allo-immune reactions, which by far exceeds 
the stimulation by a single peptide. Polyspecificity could 
explain why all TCC, which react immediately to the ad-
dition of abacavir {abacavir-pept-B * 57: 01}, always also 
reacted to abacavir-pulsed APC, where an internal pep-
tide exchange might have taken place  [35] ( fig. 2 ). Thus, 
although surface-presented and internally loaded pep-
tides differ, the TCC reactivity was unchanged. This abil-
ity to react with various peptides may also explain the 
observation that abacavir-induced TCC react similarly to 
abacavir when a battery of different abacavir-exposed 
APC (EBV transformed B-LCL, monocytes, phytohe-
magglutinin-stimulated blasts and HLA-transfected lym-
phoblastoid cell line 721.221) are used, which most likely 
present different peptides. Polyspecificity also includes 
the term heterologous immunity  [43] , which is used to 
explain prior priming of T cells by a viral peptide, for
example, followed by reactivation of the same T cell by
a cross-reactive peptHLA or {peptHLA-drug} complex 
 [43] . It is hypothesized that such a polyspecific (cross-
reactive/heterologous) reaction may explain the T cell re-
activity versus, for example, herpes virus-infected tissue, 
as the drug-induced T cells may also react with herpes 
virus pept/HLA in the tissue. 
 In summary, the model of allo-stimulation by p-i HLA 
provides a novel explanation for the capacity of small 
molecules to initiate a strong immune response without 
further cofactors. The connection of direct allo-stimula-
tion and stimulation by p-i has already been noted previ-
ously as 30% of drug-induced TCC were found to be allo-
reactive  [46] . This link may also explain why clinical fea-
tures of SJS/TEN occur not only in DHR, but also in 
 Table 2.  Comparing allo-immune and drug hypersensitivity reactions
Allo reactivity (direct) Drug hypersensitivity (p-i HLA)1
Altered HLA allo-allele drug-modified self HLA
acquiring features of an allo HLA-protein
Direct T cell stimulation allo-HLA with peptide drug-modified HLA with self- or altered 
peptide
Dendritic cell requirement and 
costimulation
no no
Stimulation of naïve T cells yes yes
Stimulation of memory T cells yes yes
Peptide specificity of TCR polyspecific2 polyspecific2
1 Investigated mainly in the abacavir model. 2 T cells react with more than one peptide (see text).
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GVHD/organ transplantation  [47–51] . However, this 
concept of direct allo-immune-like stimulation in p-i 
HLA needs to be investigated further, and whether it can 
be extended to other drugs and HLA-associated DHR has 
yet to be clarified.
 p-i TCR 
 p-i TCR refers to the direct interaction of a drug with 
αβ-TCR  [15] . In early studies with sulfamethoxazole- 
(SMX), lidocaine- and quinolone-reacting TCC- and 
TCR-transfected hybridoma cells, T cell activation was 
linked to the unique structure of the drug-reactive TCR. 
T cell stimulation required the presence of HLA mole-
cules but the immunogenic peptides bound to HLA were 
exchangeable. Even the HLA molecules were exchange-
able, as some TCC maintained reactivity in the presence 
of allogeneic APC  [52–56] . Of note, most of these charac-
teristics were shown for CD4 + TCC, restricted by MHC 
class II molecules.
 Newer data support and extend these data and lead to 
at least two models of T cell stimulation by p-i TCR  [57–
59] . Data are based on a detailed analysis of two SMX-
reacting CD4 + TCC named ‘H13’ and ‘1.3’ ( fig. 4 ) from 
the same SMX-allergic donor: the two TCC were evalu-
ated regarding proliferation to twelve different sulfanil-
amides, inhibition of SMX-induced proliferation by 
other sulfanilamides and by molecular modeling. TCC 
H13 is clearly restricted to HLA-DRB1 * 10: 01, while 
TCC 1.3 reacted with SMX even in the absence of APC, 
i.e. the TCC could self-present the drug  [57] . Data of the 
two TCC revealed that SMX bound to two different sites 
on the two distinct TCR with rather distinct functional 
consequences. In the case of TCC H13, SMX binding to 
the TCR resulted in allosteric interactions  [58] . SMX 
and five of the eleven other sulfanilamides tested were 
stimulatory in proliferation assays. These were found to 
bind outside the peptide interacting site on the TCR-
CDR2 of the β-chain. The remaining six sulfanilamides 
did not bind at all (as revealed by docking), and were not 
stimulatory. Molecular modeling of SMX binding to the 
TCR revealed that SMX bound to the CDR2 region of 
TCR-Vβ20-1. This binding induces an alteration of the 
TCR configuration which results in an increased affinity 
of TCR H13 to the HLA-DRB1 * 10: 01 and a laminin-
derived peptide (Gibbs energy between the TCR and 
pept-HLA were 7-fold higher with SMX compared to 
without SMX). Thus, drug binding to TCR can result in 
an allosteric effect which enhances the reactivity of a 
TCR to HLA with presented (self) peptides  [58] ( fig. 4 ).
 The elucidation of SMX binding to the second TCR 1.3 
resulted in a completely different picture  [57, 59]  ( fig. 4 , 
 5 ). In this case, SMX binds directly to the rather large loop 
formed by CDR3 of the α-chain of the TCR. It stimulates 
the TCR/TCC similar to a hapten-modified peptide pre-
sented by HLA-DR  [57, 60] . Interestingly, SMX stimula-
tion of this specific TCC was very strong – often stronger 
than the stimulation induced by the mitogen phytohe-
a
b
 Fig. 4. p-i TCR: SMX binding to 1.3 ( a ) and H13 ( b ).  a The bind-
ing site of SMX could be localized by docking to the CDR3/Vα of 
the TCR 1.3. Eleven other sulfanilamides were also localized by 
docking to the same position at CDR3/Vα, but these eleven sulfa-
nilamides were not stimulatory. They were, however, able to in-
hibit the SMX-induced Ca ++ influx and proliferation in TCC 1.3, 
which confirms their binding to the SMX binding site of TCR 1.3 
( fig. 5 )  [57] .  b A model of the TCR H13, with the binding site of 
SMX on CDR2 of TCR-Vβ20-1. Five other sulfanilamides also 
bind to the same region. These six sulfanilamides elicit a prolifera-
tive response if autologous APCs are present  [57] . Molecular mod-
eling revealed that SMX binding to the CDR2 region induces an 
allosteric effect which increases the binding affinity of the TCR 
with the peptHLA complex by 7-fold  [58] . 
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magglutinin. SMX-specific stimulation could be blocked 
in a dose-dependent way by any of the other eleven sulfa-
nilamides  [57] . Docking studies revealed that SMX and 
the eleven other sulfanilamide derivatives bound to the 
same binding site on CDR3α, which explains their block-
ing effect. It also shows that drug binding to TCR may or 
may not result in T cell activation  [57] . Apparently, drug 
binding without stimulation is more frequent than bind-
ing with stimulation, which is similar to other drug-recep-
tor interactions. Why are eleven sulfanilamides nonstim-
ulatory whereas one (SMX) is stimulatory? A closer look 
suggested that the nonstimulatory sulfonamides bound to 
the CDR3α pocket had their NH2 ends directed towards 
the TCR ( fig. 5 )  [57, 59] . Only SMX bound to the CDR3α 
had its NH2 group pointing to the peptide-binding groove. 
This orientation would be similar to the orientation of the 
hapten SMX-NO when it is bound to a peptide and pre-
sented on HLA. Indeed, we and others have already de-
scribed TCC which react on the one hand with SMX via 
the p-i mechanism, and on the other hand with the hapten 
SMX-NO  [60, 61] . Earlier data of TCC 1.3 revealed that it 
also reacted to SMX-NO (unpubl. data). Thus, the dock-
ing data of SMX binding to TCR-CDR3α supports and 
explains the existence of such hapten (SMX-NO) and p-i 
(SMX) cross-reactive TCC. It also shows that, under these 
stimulatory conditions, the drug molecule itself and not a 
peptide is recognized. The stimulation of TCR 1.3 was ex-
clusively dependent on SMX without the need for peptide 
recognition/interaction in combination with a particular 
HLA  [46, 57] . However, an HLA molecule was still re-
quired as a matrix. It was thus rather similar to certain 
stimulations by trinitrophenol molecules which were co-
valently bound in the middle of immunogenic peptides in 
mouse models of contact dermatitis, independent of the 
sequence and MHC allele  [62] .
 Requirements for Costimulation for p-i Stimulations 
 Costimulation from innate immunity is a crucial step 
in the development of a primary adaptive immune re-
sponse to protein or hapten-modified protein antigens. 
Indeed, chemicals acting as haptens do not only form 
neoantigens, but can also activate innate immunity and 
elicit dendritic cell maturation  [5–7] . 
 The cofactors involved in p-i TCR and p-i HLA may 
differ; no costimulation is required in the abacavir model 
of p-i HLA as the abacavir-B * 57: 01-peptide complexes 
per se act like an allo-allele and elicit a strong and direct 
T cell stimulation. The discrepancy between 100% in vitro 
response to abacavir in HLA-B * 57: 01 + individuals  [40, 
43, 63] and only 55% in vivo reactors  [22] might be re-
lated to the tolerance mechanism, similar to the tolerance 
mechanism in transplantation or pregnancy. On the oth-
er hand, p-i TCR stimulations are different and some may 
require cofactors. There are at least two possibilities: (a) 
the presence of the HLA-risk allele may become relevant 
only when an additional T cell clonotype is present, and 
(b) activation of T cells by concomitant infection with the 
release of cytokines and upregulation of adhesion mole-
cules may lower the threshold of T cell reactivity. 
 The high negative predictive value for carbamazepine 
hypersensitivity in HLA-B * 15: 02 + individuals and the 
low positive predictive value suggested that this allele is a 
crucial yet not sufficient risk factor for carbamazepine hy-
persensitivity syndrome  [33, 34] . Ko et al.  [33] showed 
that carbamazepine-reacting T cells from HLA-B * 15: 02 + 
patients with SJS/TEN used mainly the TCR Vβ-11-
ISGSY clonotype. This clonotype was present in 16 out of 
a
b
 Fig. 5. p-i TCR: orientation of sulfanilamide binding into the 
CDR3/Vα of the TCR 1.3.  a The sulfanilamides localize into the 
large loop of the CDR3/Vα of TCR 1.3: the nonstimulatory sulfa-
nilamides had their NH2 ends directed towards the TCR  [57, 59] . 
 b Only the stimulatory SMX can bind to the CDR3/Vα in an in-
verse orientation, with its NH2 group pointing to the peptide-
binding groove  [57] .  
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19 patients and was absent in all 17 carbamazepine-toler-
ant patients. Moreover, in PBMC of healthy subjects who 
are carriers of HLA-B * 15: 02 and of Vβ-11-ISGSY, carba-
mazepine-specific cytotoxicity could also be primed in vi-
tro. Thus, the data suggest that only if both a certain HLA 
and a certain TCR-sequence are present, a strong and dis-
ease-causing T cell stimulation can develop  [33, 34] . 
 In p-i TCR, the analysis of SMX reactivity of TCC H13 
revealed that the binding site on the TCR Vβ20.1 is not 
unique for a particular individual, but is present in all in-
dividuals. Approximately 0.8–2.4% of normal circulating 
T cells express the Vβ20.1. Epidemiology suggests that 
only around 3% of SMX-treated individuals develop al-
lergy upon drug exposure  [64] . However, during the early 
years of the HIV epidemic, when patients with HIV infec-
tion and T cell immunodeficiency received SMX/trime-
thoprim (SMX/TMP) as a prophylaxis against opportunis-
tic infections, cutaneous, allergy-like side effects to SMX/
TMP occurred in 30–50% of treated HIV-positive patients 
 [65, 66] . ‘Sulfa-allergy’ is also more prevalent in patients 
with active autoimmune disease  [67] . A possible explana-
tion may lie in the massive immune activation caused by 
the HIV infection with the upregulation of adhesion mol-
ecules, enhanced expression of HLA molecules and in-
creased cytokine production, which lowers the activation 
threshold of TCR-Vβ 20.1 + T cells to react to SMX. Thus, 
while SMX binding to TCR-Vβ20.1 + per se is probably in-
sufficient to elicit DHR, the additional presence of gen-
eralized immune activation with a lowered threshold for
T cell reactivity may be sufficient for T cell activation. Of 
note, not all p-i TCR require costimulation; the binding of 
SMX to TCR 1.3 may result in activation without costimu-
lation as this stimulation is very strong per se and linked 
to a particular and rather unique TCR  [57] .
 The p-i Concept: A Particular 'Off-Target' Activity of 
a Drug 
 The features of drug receptor interactions as elucidat-
ed in the p-i concept do actually correspond to an ‘off-
target’ activity of a drug, namely that drugs do not only 
bind to their intended targets, but also to other proteins/
receptor structures. Such ‘off-target’ activities may actu-
ally occur rather frequently, as these immune receptors 
are very polymorphic. One estimate is that there are
about 10 11 TCR per individual and over 10,000 different 
HLA class I and more than 3,000 HLA class II alleles
in the human population (http://www.allelefrequencies.
net/hla6006a.asp). Thus, the chance of a drug finding a 
suitable binding site within some of the polymorphic im-
mune receptors is probably higher than with monomor-
phic receptor structures. The majority of such drug-re-
ceptor interactions within the immune system may occur 
without functional consequences. However, a few drugs 
may bind at a relevant position on the TCR or HLA mol-
ecule and be affine enough to cause functional conse-
quences.
 To consider the p-i concept as an ‘off-target’ activity of 
a drug on immune receptors is intriguing. It is also help-
ful to emphasize the pharmacological basis of the reac-
tion. However, the ‘off-target’ activity of a drug on the 
immune receptor has many – and in particular more 
complex – implications than the usual off-target reac-
tions on a receptor of a certain tissue cell and, thus, the 
term p-i concept is justified and should be kept. A main 
distinction between the p-i concept and usual off-target 
activities of drugs is the fact that the effect may be indi-
rect. It is not the cell, whose receptor was altered by drug 
binding, but a reactive T cell that is responsible for the 
symptoms. In p-i HLA, it is not the drug-modified APC, 
but rather the reactive T cell which causes clinical symp-
toms by secreting cytokines or mediating cytotoxicity. In 
p-i TCR, the functional consequence is due to an interac-
tion between the T cell and the HLA-peptide complex on 
APC. In usual off-target activities, the effect is confined 
to the cells carrying the off-target receptor.
 Another complication is the great heterogeneity of the 
immune system. While usual off-target activities result in 
a consistent and homogeneous result, the functional con-
sequence of p-i TCR or p-i HLA are as complex as the 
immune system itself. In p-i TCR, not all but only some 
TCR are activated. It is a drug-receptor-driven stimula-
tion, but it looks like an antigen-driven stimulation. The 
immune reaction induced is actually a reflection of the 
available T cell repertoire and may mirror the prior expe-
rience of the individual. The clinical manifestations can 
be very heterogeneous, with features such as cytotoxic, 
suppressor, helper, etc. Similarly, in p-i HLA, an allo-like 
immune response may evolve which is often polyclonal 
and clinically as heterogeneous as a GVHD reaction.
 Last but not least, the complexity of clinical pictures is 
not only related to drug binding to different immune re-
ceptors like HLA, TCR or both TCR and HLA, but differ-
ences may also be due to the strength/affinity/exact loca-
tion of drug binding to the immune receptors involved. 
All these important distinctions between ‘simple’ and 
‘complex’ off-target reactions justify keeping the term
‘p- i concept’ as a separate entity.
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 Can Other Endogenous Small Molecules Also Be 
Involved in Abnormal T Cell Stimulations?  
 If small molecules like drugs can under certain circum-
stances elicit such severe diseases like SJS/TEN or DRESS, 
is it possible that other endogenous small molecules can 
under certain circumstances also be harmful? There are 
two arguments to support this possibility. First, there is the 
above-mentioned argument that the unique HLA-restric-
tion of certain diseases are better explained by the binding 
of small-molecule-like drugs to a unique pocket in an in-
criminated HLA allele rather than by an HLA-presented 
peptide, as the latter normally also binds to other similar 
HLA alleles. Second, Yun et al.  [36] have described T cell 
lines which react to xanthine. The reacting T cells were ini-
tiated by oxypurinol, but mounted cytotoxic reactivity also 
to xanthine, a small endogenous molecule. Therefore, a 
small, endogenously produced molecule may stimulate an 
immune reaction under certain circumstances  [68] . A po-
tential role of small molecules as a trigger for an immune 
reaction was hitherto not considered, since they were ex-
cluded based on immunological data and exclusive focus-
ing on hapten characteristics. However, small molecules 
have apparently different ways to stimulate the immune 
system. Importantly, while a rather exclusive HLA associa-
tion may be an indication for the involvement of small 
molecules in a hypersensitivity disease, it is no prerequisite, 
as some small molecules may bind to various HLA alleles.
 Conclusion 
 The described features of the p-i concept opens a Pan-
dora’s box of possible interferences of small molecules 
with the immune system. Many of the peculiar in vitro, in 
vivo and clinical features of drug allergies can be ex-
plained by p-i TCR and p-i HLA, and this concept may 
also apply to diseases beyond DHR. However, while the 
essence of the p-i concept is quite well established, the 
data and conclusions described in this review are still lim-
ited and are mainly based on a detailed analysis of a few 
drugs. Further verification and extension of p-i interac-
tions with other molecules and analysis of functional con-
sequences is needed. 
 The link of DHR to an allo-like immune stimulation 
should remind us of certain limitations of modern medi-
cine. Two main causes of iatrogenic diseases, allotrans-
plant rejection/GVHD and DHR, can be traced back to 
the same problem, namely how the specific immune sys-
tem learns to discriminate self from non-self. It shows us 
that modern medicine introduces new players like organ/
bone marrow transplantation and extensive pharmaco-
therapy with many novel chemicals into a system that has 
developed over millions of years, but was never prepared 
for such ‘artificial’ interventions. Understanding these 
limitations may be an important first step and may help 
to overcome and avoid iatrogenic diseases like DHR. In 
addition, it may possibly uncover other unknown causes 
of ‘modern’ diseases.
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